Eli Lilly (LLY) Plans $7B Acquisition, P/E at 40 Amid Growth

Eli Lilly (LLY) announced plans to acquire Kelonia Therapeutics for approximately $7 billion, a move intended to strengthen its gene therapy pipeline. The company reported a year-over-year revenue increase of 43% and earnings per share growth of 51% during the fourth quarter. Its current forward-looking price-to-earnings (P/E) ratio stands at 40, below its five-year average of 56. With health spending growing by 7.2% from 2023 to 2024, managing competition in the weight-loss sector remains crucial for Lilly's future growth.